Zurcher Kantonalbank Zurich Cantonalbank Decreases Stake in Cryoport, Inc. (NASDAQ:CYRX)

Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Cryoport, Inc. (NASDAQ:CYRX) by 29.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,075 shares of the company’s stock after selling 3,387 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Cryoport were worth $125,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of CYRX. Skylands Capital LLC grew its position in Cryoport by 23.7% during the 3rd quarter. Skylands Capital LLC now owns 84,950 shares of the company’s stock worth $1,165,000 after purchasing an additional 16,300 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Cryoport during the 3rd quarter worth approximately $3,250,000. Quantbot Technologies LP grew its position in Cryoport by 109.0% during the 3rd quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock worth $176,000 after purchasing an additional 6,694 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Cryoport by 28.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,356,500 shares of the company’s stock worth $18,598,000 after purchasing an additional 298,995 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Cryoport by 5.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 354,023 shares of the company’s stock worth $4,854,000 after purchasing an additional 17,024 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Price Performance

Shares of NASDAQ CYRX opened at $13.46 on Friday. The firm has a market cap of $661.75 million, a PE ratio of -6.12 and a beta of 1.60. The firm has a fifty day moving average of $16.78 and a 200 day moving average of $15.19. The company has a debt-to-equity ratio of 0.82, a quick ratio of 11.16 and a current ratio of 11.73. Cryoport, Inc. has a one year low of $9.00 and a one year high of $23.50.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. The company had revenue of $54.59 million during the quarter, compared to analysts’ expectations of $58.78 million. During the same period in the previous year, the firm posted ($0.16) EPS. Cryoport’s revenue was down 13.1% compared to the same quarter last year. As a group, research analysts predict that Cryoport, Inc. will post -1.42 EPS for the current fiscal year.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 2,631 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $46,147.74. Following the completion of the sale, the chief executive officer now owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Jerrell Shelton sold 2,631 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $46,147.74. Following the completion of the sale, the chief executive officer now owns 692,182 shares of the company’s stock, valued at $12,140,872.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the completion of the sale, the director now directly owns 43,187 shares of the company’s stock, valued at approximately $633,985.16. The disclosure for this sale can be found here. Insiders sold 73,940 shares of company stock valued at $1,147,538 over the last 90 days. 10.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on CYRX. Stephens reissued an “equal weight” rating and set a $17.00 target price on shares of Cryoport in a research report on Wednesday, March 13th. UBS Group lifted their price objective on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a research note on Friday, March 15th. B. Riley cut shares of Cryoport from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Needham & Company LLC restated a “buy” rating and set a $18.00 price objective on shares of Cryoport in a research note on Wednesday. Finally, Jefferies Financial Group initiated coverage on shares of Cryoport in a research note on Thursday, April 4th. They set a “buy” rating and a $21.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Cryoport presently has a consensus rating of “Hold” and an average target price of $18.25.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.